Publications

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Journal: Lancet
published: 2017 Jan 23

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).

Journal: Lung Cancer
published: 2017 Jan

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Journal: J Clin Oncol.
published: 2017 Jan 10

Stratified Treatment in Lung Cancer

Journal: Onol Res Treat
published: 2016 Nov 24

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. oncology.

Journal: Pathologe
published: 2016 Nov 1

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology.

Journal: Ann Oncol.
published: 2016 Sep. 27

Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a TP53 Context-specific Manner.

Journal: Mol Cancer Res.
published: 2016 Aug 11

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Journal: Mod Pathol
published: 2016 Jul 8

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.

Journal: Clin Cancer Res.
published: 2016 Jun 1

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.

Journal: J Thorac Oncol
published: April 11, 2016

ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

Journal: Pneumologie
Published: April 1st, 2016

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

Journal: Oncoimmunology
published: 2016 March 16

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Journal: Lancet Oncol.
Published: March 6th, 2016

Clinicopathological characteristics of RET rearranged lung cancer in European patients

Journal: IASLC
Published: January 11, 2016

NOTCH, ASCL1, p53 und RB Änderungen definieren einen alternativen Weg Fahr neuroendokrinen und kleinzelligen Lungenkarzinomen.

Journal: Int J. Cancer
Published: September 5th, 2015

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

Journal: Exp Mol Pathol
Published: November 6th, 2015

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Journal: Oncologist
Published: October 20, 2015

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

Journal: J Thorac Oncol.
Published: 10. October 2015

NOTCH, ASCL1, p53 und RBNOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Journal: Int J. Cancer
published 4th of September, 2015

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Journal: AAPS J.
published 19th of August, 2015

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Journal: Eur J Nucl Med Mol Imaging
Published: 18. Aug. 2015

Comprehensive genomic profiles of small cell lung cancer.

Journal: Nature
Published: 6. Aug. 2015

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

Journal: J Thorac Oncol
Published: Jul. 2015

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Journal: Cell
Published: 2nd of july, 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Journal: J Thorac Oncol
Published: June 10, 2015

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Journal: Oncotarget
Published: April 30, 2015

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Journal: J. Clin Oncol.
Published: 20. March 2015

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Journal: Lancet Oncol
Published: March 16th, 2015

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung

Journal: Clin Cancer Res
Published: February 15th, 2015

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Journal: Lung Cancer
Published: Feb. 2015

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

Journal: Lung Cancer
Published: Feb. 2015

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Journal: Oncotarget
Published: January 20th, 2015

Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.

Journal: J Thorac Oncol
Published: January 10th, 2015

PD-L1 expression in small cell neuroendocrine carcinomas.

Journal: Eur J Cancer
Published: January 9, 2015

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Journal: Genome Biol
Published: January 5th, 2015

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Journal: Clin Cancer Res
Published: December 9th, 2014

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Journal: Lancet Respir Med
Published: December 2nd, 2014

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Journal: Int J Radiat Oncol Biol Phys
Published: December 1st, 2014

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Journal: Oncotarget
Published: November 26th, 2014

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Journal: Nat Med
Published: September 20, 2014

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

Journal: J Thorac Oncol
Published: 12. September 2014

CD74-NRG1 Fusions in Lung Adenocarcinoma

Journal: Cancer Discov
Published: April 4th, 2014

Ceritinib in ALK-rearranged non-small-cell lung cancer

Journal: N Engl J Med
Published: March 27th, 2014

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Journal: Nat Commun.
Published: March 27th, 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

Journal: Cancer Discov
Published: February 4th, 2014

A Genomics-Based Classification of Human Lung Tumors

Journal: Science Translational Medicine
Published: October 2013

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer

Journal: Modern Pathology
Published: July 2013

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Journal: Lung Cancer
Published: July 2013

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Journal: Translational lung cancer research
Published: April 2013

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Journal: Translational lung cancer research
Published: April 2013

Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Journal: Journal of Clinical Investigation
Published: April 2013

Lung Cancer: Molecular pathology and personalized therapy

Journal: Der Internist
Published: February 2013

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

Journal: Journal of Clinical Oncology
Published: May 2013

Molecular pathology of the lungs. New perspectives by next generation sequencing

Journal: Der Pathologe
Published: February 2013

Prognostic Impact of Fluorothymidine andFluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Journal: PLoS One
Published: January 2013

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

Journal: Clinical Cancer Research
Published: December 2012

Genetic insight and therapeutic targets in squamous-cell lung cancer

Journal: Oncogene
Published: November 2012

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Journal: Proc Natl Acad Sci USA
Published: October 2012

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Journal: Nature Genetics
Published: October 2012

Comprehensive genomic characterization of squamous cell lung cancers

Journal: Nature
Published: September 2012

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Journal: Clinical Cancer Research
Published: September 2012

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Journal: Journal of Clinical Oncology
Published: September 2012

Indications and limitations of fresh frozen sections in the pulmonary apparatus

Journal: Der Pathologe, Vol 33, No 5, September 2012, doi: 10.1007/s00292-012-1603-y
Published: September 2012

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Journal: Cell
Published: September 2012

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Journal: Lung Cancer
Published: September 2012

Early palliative care for patients with metastatic cancer

Journal: Current Opinion in Oncology
Published: July 2012

Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Journal: European Journal of Nuclear Medicine & Molecular Imaging
Published: July 2012

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Journal: Clinical Nuclear Medicine
Published: 2012

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Journal: Clinical Cancer Research
Published: May 2012

Recommending early integration of palliative care – does it work?

Journal: Support Care Cancer
Published: March 2012

Personalized therapy of lung cancer

Journal: Onkologie
Published: February 2012

The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study

Journal: BMC Research Notes
Published: January 2012

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Journal: Clinical Cancer Research
Published: December 2011

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

Journal: Journal of Thoracic Oncology
Published: December 2011

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

Journal: Journal of Nuclear Medicine
Published: December 2011

A crucial requirement for Hedgehog signaling in small cell lung cancer

Journal: Nature Medicine
Published: October 2011

Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

Journal: Clinical Pharmacokinetics
Published: September 2011

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Journal: Cancer Research
Published: July 2011

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines

Journal: Clinical pharmacokinetics
Published: June 2011

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Journal: Cancer Discovery
Published: June 2011

Blood-based gene expression signatures for early detection of lung cancer

Journal: Clinical Cancer Research
Published: May 2011

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Journal: PLoS One
Published: May 2011

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Journal: Journal of Clinical Oncology
Published: May 2011

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

Journal: Journal of Clinical Oncology
Published: March 2011

Molecular diagnostics of lung cancer for treatment stratification

Journal: Der Internist
Published: February 2011

Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer

Journal: Science Translational Medicine
Published: December 2010

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Journal: Nucleic Acids Research
Published: November 2010

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Journal: Cell
Published: October 2010

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium

Journal: Journal of the National Cancer Institute
Published: July 2010

Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project

Journal: Journal of palliative medicine
Published: June 2010

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Journal: Journal of Medicinal Chemistry
Published: April 2010

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors

Journal: Journal of Thoracic Oncology
Published: March 2010

Identification of lung cancer with high sensitivity and specificity by blood testing

Journal: Respiratory Research
Published: February 2010

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Journal: Cancer Research
Published: February 2010

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

Journal: PLoS One
Published: January 2010

Last update: 14. March 2016 , 14:49

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.

Share This